Previous 10 | Next 10 |
Meridian Bioscience ( VIVO ) fiscal Q3 results : More news on: Meridian Bioscience, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Meridian Bioscience (NASDAQ: VIVO ) : Q3 Non-GAAP EPS of $0.56 beats by $0.33 ; GAAP EPS of $0.64 beats by $0.45 . More news on: Meridian Bioscience, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
CINCINNATI, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020. Third Quarter Fiscal 2020 Highlights: Consolidated Net Revenue of $84.8 million, up 75% year-over-year Life Sci...
Investment Thesis Beyond COVID-19 diagnostic test sales, Meridian Bioscience Inc ( VIVO ) core businesses are facing increased competition that the company historically failed to handle. This is demonstrated by lower revenues and decreased margin before the COVID-19 bonanza. The company ...
CINCINNATI, July 28, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately. “We welcome Tony to the board as a new independent director and look forward to the leadership he ...
Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...
Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock, often with a focus on a specific sector. Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms o...
CINCINNATI, July 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2020 financial results Friday, August 7, 2020. Jack Kenny, Chief Executive Officer, and Bryan Balda...
CINCINNATI, July 13, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rap...
Introduction Through Week 26 of 2020, the Premium Portfolio has gained +14.43%, substantially leading the S&P 500 benchmark by +21.29%. These returns were achieved by actively trading in 11 fewer weeks (nearly halted for an entire quarter) using the alerts of the Momentum Gauge™ t...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...